Surrogate endpoints: can size of effect mitigate perplexity?
Lancet Oncol
.
2013 Jun;14(7):568-9.
doi: 10.1016/S1470-2045(13)70196-7.
Epub 2013 May 14.
Author
Francesco Perrone
1
Affiliation
1
Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy. f.perrone@istitutotumori.na.it
PMID:
23680110
DOI:
10.1016/S1470-2045(13)70196-7
No abstract available
Publication types
Comment
MeSH terms
Biomarkers*
Carcinoma, Non-Small-Cell Lung / mortality*
Chemoradiotherapy / mortality*
Humans
Lung Neoplasms / mortality*
Substances
Biomarkers